Wakamoto Pharmaceutical Co (TSE:4512) Retained Earnings: 円842 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4512 Wakamoto Pharmaceutical Co Ltd TSE:4512
63 GF Score
Price 円269.00
GF Value 円319.94
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Wakamoto Pharmaceutical Co Retained Earnings?

Wakamoto Pharmaceutical Co TSE:4512 -1.10% 63 Retained Earnings is 円842 Mil as of Mar. 2026. GuruFocus rates TSE:4512 with a GF Score™ of 63/100 and a GF Value™ of 円319.94 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Wakamoto Pharmaceutical Co's retained earnings for the quarter that ended in Mar. 2026 was 円842 Mil.

Wakamoto Pharmaceutical Co's quarterly retained earnings increased from Mar. 2025 (円719 Mil) to Sep. 2025 (円4,433 Mil) but then declined from Sep. 2025 (円4,433 Mil) to Mar. 2026 (円842 Mil).

Wakamoto Pharmaceutical Co's annual retained earnings declined from Mar. 2024 (円758 Mil) to Mar. 2025 (円719 Mil) but then increased from Mar. 2025 (円719 Mil) to Mar. 2026 (円842 Mil).


Wakamoto Pharmaceutical Co  (TSE:4512) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Wakamoto Pharmaceutical Co Retained Earnings Historical Data

* Premium members only.

The historical data trend for Wakamoto Pharmaceutical Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wakamoto Pharmaceutical Co Retained Earnings Chart

Wakamoto Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 615.21 753.46 758.30 718.62 841.72

Wakamoto Pharmaceutical Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 758.30 4,465.47 718.62 4,433.49 841.72
TSE:4512
63GF Score
Wakamoto Pharmaceutical Co Ltd TSE:4512
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wakamoto Pharmaceutical Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of 円842 Mil mean?
Wakamoto Pharmaceutical Co (TSE:4512) has a Retained Earnings of 円842 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Wakamoto Pharmaceutical Co and its competitors.
Is Wakamoto Pharmaceutical Co's Retained Earnings too high?
Wakamoto Pharmaceutical Co's current Retained Earnings is 円842 Mil. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's Retained Earnings compare to ZTS?
Wakamoto Pharmaceutical Co's Retained Earnings of 円842 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Wakamoto Pharmaceutical Co and its competitors. Wakamoto Pharmaceutical Co's current Retained Earnings is 円842 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Modestly Undervalued. The stock's GF Value™ is 円319.94, compared to a current price of 円269.00 — trading 15.9% below its estimated fair value. The current Retained Earnings is 円842 Mil. Wakamoto Pharmaceutical Co's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current Retained Earnings is 円842 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?

Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued. The current stock price of 円269.00 is trading 15.9% below its estimated GF Value™ of 円319.94. GuruFocus considers Wakamoto Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4512:

  • Retained Earnings: 円842 Mil
  • GF Value™: 円319.94 vs. price of 円269.00 (15.9% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Wakamoto Pharmaceutical Co Business Description

Address 2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-8330
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
63GF Score

Get the complete analysis for TSE:4512

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円269.00
Price
円319.94
GF Value